Publications by authors named "Matteo Caridi"

Claim this Profile
T
Targeting metabotropic glutamate receptors for symptomatic and disease-modifying treatment in Parkinson's disease.
Marika Alborghetti, Alessia Ceccherelli, Matteo Caridi, Ferdinando Nicoletti, Giuseppe Battaglia

NPJ Parkinsons Dis· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Venetoclax plus azacitidine as genetic-driven bridge-to-transplant therapy for IDH2-mutated acute myeloid leukaemia (AML) refractory to intensive chemotherapy: proof-of-concept case reports.
Gaetano Cimino, Matteo Caridi, Valeria Cardinali, Sofia Sciabolacci, Sara De Santis

Ann Hematol· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacological Blockade of Group II Metabotropic Glutamate Receptors Reduces the Incidence of Brain Tumors Induced by Prenatal Exposure to N-ethyl-N-nitrosourea in Rats.
Antonietta Arcella, Marika Alborghetti, Anna Traficante, Maria Antonietta Oliva, Sabrina Staffieri, Matteo Caridi

Curr Neuropharmacol· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Impact of Radiotherapy and Attenuated Chemotherapy Regimens in Older Patients with Classic Hodgkin Lymphoma: A Real-Life Study from the ReLLi Network.
Maria Christina Cox, Matteo Caridi, Alexandro Patirelis, Ilaria Del Giudice, Alessandro Pulsoni

Cancers (Basel)· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Metabotropic Glutamate Receptors Type 3 and 5 Feature the "NeuroTransmitter-type" of Glioblastoma: A Bioinformatic Approach.
Matteo Caridi, Marika Alborghetti, Valeria Pellicelli, Rosamaria Orlando, Francesco Ernesto Pontieri

Curr Neuropharmacol· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction to: One disease, two faces: clonally-related AML and MPDCP with skin involvement.
Giovanni Martino, Gaetano Cimino, Matteo Caridi, Giuseppe Perta, Valeria Cardinali

Ann Hematol· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction: Bocci et al. Remarkable Remission Rate and Long-Term Efficacy of Upfront Metronomic Chemotherapy in Elderly and Frail Patients, with Diffuse Large B-Cell Lymphoma. 2022, , 7162.
Guido Bocci, Sabrina Pelliccia, Paola Orlandi, Matteo Caridi, Marta Banchi

J Clin Med· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
One disease, two faces: clonally-related AML and MPDCP with skin involvement.
Giovanni Martino, Gaetano Cimino, Matteo Caridi, Giuseppe Perta, Valeria Cardinali

Ann Hematol· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Remarkable Remission Rate and Long-Term Efficacy of Upfront Metronomic Chemotherapy in Elderly and Frail Patients, with Diffuse Large B-Cell Lymphoma.
Guido Bocci, Sabrina Pelliccia, Paola Orlandi, Matteo Caridi, Marta Banchi

J Clin Med· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The metronomic all-oral DEVEC is an effective schedule in elderly patients with diffuse large b-cell lymphoma.
M Christina Cox, Sabrina Pelliccia, Luigi Marcheselli, Roberta Battistini, Annalisa Arcari, Matteo Caridi

Invest New Drugs· June 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis